{"id":"galantamine-cr","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Vomiting"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"1-3","effect":"Syncope"},{"rate":"1-3","effect":"Bradycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting acetylcholinesterase, galantamine elevates synaptic acetylcholine concentrations, which helps improve cognitive function in neurodegenerative diseases. Additionally, galantamine enhances the function of nicotinic acetylcholine receptors through allosteric modulation, providing a dual mechanism of action. The CR (controlled-release) formulation extends drug exposure to allow once-daily dosing.","oneSentence":"Galantamine is a cholinesterase inhibitor that increases acetylcholine levels in the brain by blocking its breakdown, and also acts as an allosteric modulator of nicotinic receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:55.976Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate Alzheimer's disease"},{"name":"Cognitive decline associated with Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT01921972","phase":"PHASE4","title":"The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2004-11","conditions":"Alzheimer's Disease","enrollment":232},{"nctId":"NCT00211588","phase":"NA","title":"Galantamine Executive Function in Parkinson's Disease","status":"UNKNOWN","sponsor":"Memorial Hospital of Rhode Island","startDate":"2004-06","conditions":"Parkinson's Disease","enrollment":90},{"nctId":"NCT00181636","phase":"NA","title":"Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"","conditions":"Bipolar Disorder","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Razadyne-ER"],"phase":"marketed","status":"active","brandName":"Galantamine-CR","genericName":"Galantamine-CR","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Galantamine-CR is a medication that has been studied for its potential use in treating Alzheimer's Disease, Parkinson's Disease, and Bipolar Disorder. It is a controlled-release formulation of galantamine, a medication that works by inhibiting acetylcholinesterase, an enzyme involved in the breakdown of acetylcholine, a neurotransmitter in the brain.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-04-01T00:00:00.000Z","mah":"JANSSEN PHARMS","brand_name_local":"RAZADYNE ER","application_number":"NDA021615"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}